Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lavera launches U.S. test program

This article was originally published in The Rose Sheet

Executive Summary

German naturals firm Lavera will launch its products in six Harmon stores in New Jersey and two Bed Bath & Beyond stores in New York beginning in the spring under a deal announced Jan. 7. Harmon, a key health and beauty retailer in the Atlantic Northeast region, is a subsidiary of housewares store Bed Bath & Beyond. "Harmon is a very progressive company. It has built its success and reputation on providing the best, price-competitive choices for its customers, and we believe that inclusion of our organic and natural skin-care products will be particularly well appreciated by their customers," says Ulrike Jacob-Dewor, CEO of Lavera North America. Lavera holds 27% market share in general health and beauty products in Europe. Its offerings currently are sold in the U.S. and Canada in Whole Foods, Wegmans, Rexall and Pharma Plus doors, as well as independent natural products stores...
Advertisement
Advertisement
UsernamePublicRestriction

Register

RS015173

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel